Comparison of Paclitaxel-Coated Balloons Against Drug-Eluting Bioresorbable Scaffolds for Elective PCI Using OCT

Coronary Artery Disease Clinical Trial

— OCTOPUS-3  

Official title:

Comparison of a Paclitaxel-Coated Balloon Without Stent Implantation Against a Drug-Eluting Bioresorbable Scaffold for Treatment of Stable Coronary Artery Disease: A Prospective Randomized Study Using Optical Coherence Tomography

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02607241
• Other study ID #: UKJ-TCP-3
• Status: Terminated
• Phase: Phase 4
• Start date: November 2015
• Est. completion date: October 2018

Study information

• Verified date: October 2018
• Source: University of Jena
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This prospective randomized clinical trial aims to compare two different "metal-free" strategies for elective percutaneous coronary revascularization: the FFR-guided DCB-only PCI (drug-coated balloon: SeQuent Please™, B Braun Melsungen GmBH) vs. OCT-guided BRS implantation (bioresorbable scaffold: Absorb™, Abbott Vascular).

Description:

Background:

Coronary artery disease (CAD) accounts for most deaths in the industrialized countries due to its high prevalence of 6-8%. CAD is mainly treated by percutaneous coronary interventions (PCI), which currently involve in over 90% of cases the implantation of metallic stents, mostly as drug-eluting devices(DES). Despite continuous technological advancement over the last decade, DES are still limited at long-term follow-up by restenosis and also by the risk of thrombosis, occurring in 5-20% and respectively 0.5-1.7% of cases. Therefore, two metal-free strategies are evaluated in order to overcome these intrinsic limitations of DES:

1. Bioresorbable scaffolds (BRS) proved comparable safety and efficacy at 1 year compared to best-in-class DES comparators and also showed in small substudies very promising 5-year results with restoration of vasomotricity and positive vessel remodeling. Optical coherence tomography (OCT) is the new gold standard for endovascular imaging of stents, atherosclerosis progression, vulnerable plaque and neointimal proliferation. OCT is currently recommended for both guidance of implantation and for assessment of long-term results of BRS.

2. Drug-coated balloons (DCB) were mainly employed to treat restenosis in metallic stents, but newer reports advocate their potential to be used as stand-alone treatment of de-novo stenoses without stenting, especially when fractional flow reserve (FFR) measurements are additionally used to assess PCI results.

This clinical trial evaluates the FFR-guided DCB-only (experimental arm: SeQuent Please™, B Braun Melsungen GmBH) PCI against the OCT-guided BRS implantation (comparator arm: Absorb™, Abbott Vascular) for treatment of stable CAD. The trial is designed as a non-inferiority, nationally conducted, multicenter, open-labeled, controlled study using a 1:1 block randomization and am invasive 6-9 month follow-up (f/u) by quantitative coronary angiography (QCA) and OCT.

Beyond the pre-specified endpoints the study mainly looking at suppression of neointimal proliferation, we will also investigate the patterns of healing and neointimal proliferation, the plaque morphology and neoatherosclerosis f/u using OCT at 6-9 months. Clinically, we attempt to record the major adverse cardiovascular events (MACE: acute myocardial infarction, cardiac death, TLR) up to 5 years after the index procedure.

A number of 196 patients scheduled for PCI with a native coronary stenosis suitable for BRS implantation and OCT imaging will be openly 1:1 randomized. This number of patients is considered to be sufficient to prove non-inferiority of DCB-only vs. BRS, using a margin of 0.2 mm with a confidence interval of 0.5 mm for the primary endpoint (diameter NLG).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 59
• Est. completion date: October 2018
• Est. primary completion date: February 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• written consent

• indication for elective PCI of a de novo coronary stenosis in a native vessel

• coronary multivessel disease with clinically proven indication for repeating coronary angiography at 6-9 months (staged PCI strategy)

Exclusion Criteria:

• pregnancy, lactation, women of childbearing age w/o reliable contraception

• life expectance < 50 % at 1 year

• major surgery planned within 6 months

• participation in other clinical trials or impossibility to give written consent

• acute coronary syndrome or cardiogenic shock within the last 4 weeks

• stent thrombosis, defined as "probable" or "definite" by ARC

• contraindication against dual antiplatelet therapy

• allergy against mTOR-inhibitors or taxol derivates

• target lesion situated in the left main coronary artery, in a bypass graft or a grafted vessel

• reference luminal diameter of the target lesion > 3.75 mm or < 2.0 mm

• lesion length > 30 mm, bifurcation lesion requiring intervention on a major side branch

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Myocardial Ischemia

Intervention

Device:
• OCT-guided BRS implantation
Implantation of a BRS using OCT to measure vessel size, choose BRS size and length and assess implantation results and the need of further postdilations
• FFR-guided DCB-only PCI
PCI performed under FFR guidance using following algorithm: (1) predilation followed by angiographic assessment of residual stenosis and dissections; (2) evaluate suitability for DCB-only, which is deemed feasible if the FFR > 0.8, residual diameter stenosis < 40% and no flow-limiting dissections are observed; (3) DCB dilation and (4) assessment of final results using FFR and QCA measurements. Provisional stenting is allowed only if the final PCI results are not acceptable (flow-limiting dissection, residual stenosis > 40% or FFR < 0.8).

Locations

Country	Name	City	State
Germany	University Hospital of Jena, Heart Center, Division of Cardiology	Jena

Sponsors (2)

Lead Sponsor	Collaborator
University of Jena	KKS Netzwerk

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Acute TVF	Target vessel failure requiring emergent revascularization	0-9 months
Primary	Angiographic NLG	Absolute net luminal diameter gain measured by QCA as minimal luminal diameter at f/u - minimal luminal diameter at baseline within the region of interest	6-9 months
Secondary	Volumetric NLG	Absolute net luminal volumetric gain using three-dimensional OCT-based vessel segment reconstruction at f/u	6-9 months
Secondary	Angiographic and volumetric LLL	Absolute late luminal diameter loss (LLL) using QCA and late luminal volumetric loss by OCT at f/u	6-9 months
Secondary	TLR	% clinically driven target lesion revascularization (TLR) during f/u	0-9 months